Oncology / Haematology

A Phase 3, randomized, double-blinded, placebo-controlled study of Tiragolumab, an anti-Tigit-antibody, in combination with atezolizumab compared with placebo in combination with atezolizumab in patients with previously untreated locally advanced unresectable or metastatic PD-L1-selected Non-small cell lung cancer

Trial Name: SKYSCRAPER1  PI: Dr Nicole Potasz

Who can take part:

  • Patients with histologically or cytologically documented locally advanced or recurrent NSCLC that is not eligible for curative surgery and/or definitive radiotherapy with or without chemotherapy, or metastatic Stage IV NSCLC
  • Patients with No prior systemic treatment for metastatic NSCLC
  • Tumor PD-L1 expression with a TPS 50%

Exclusion criteria:

  • NSCLC known to have a mutation in the EGFR gene or an ALK fusion oncogene are excluded from the study
  • Symptomatic, untreated, or actively progressing central nervous  system (CNS) metastases

For further information please contact Sally Heath – 03 9784 7290

Trial Phase

Non-drug Phase 1 Phase 2 Phase 3 Phase 4